Lee D Cranmer

  • 3633 Citations
  • 27 h-Index
1991 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Lee D Cranmer is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles
Melanoma Medicine & Life Sciences
Sarcoma Medicine & Life Sciences
Muromegalovirus Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Skin Neoplasms Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1991 2019

  • 3633 Citations
  • 27 h-Index
  • 62 Article
  • 3 Review article
1 Citation (Scopus)
Open Access
Sarcoma
Doxorubicin
Therapeutics
Survival
Anthracyclines
1 Citation (Scopus)

Systemic Interferon-g Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a phase 0 clinical trial

Zhang, S., Kohli, K., Graeme Black, R., Yao, L., Spadinger, S. M., He, Q., Pillarisetty, V. G., Cranmer, L. D., Van Tine, B. A., Yee, C., Pierce, R. H., Riddell, S. R., Jones, R. L. & Pollack, S. M., Jan 1 2019, In : Cancer Immunology Research. 7, 8, p. 1237-1243 7 p.

Research output: Contribution to journalArticle

Interferons
Synovial Sarcoma
Clinical Trials
Liposarcoma
T-Lymphocytes
5 Citations (Scopus)

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

Clark, J. I., Singh, J., Ernstoff, M. S., Lao, C. D., Flaherty, L. E., Logan, T. F., Curti, B., Agarwala, S. S., Taback, B., Cranmer, L. D., Lutzky, J., Luna, T. L., Aung, S. & Lawson, D. H., Jul 27 2018, In : Journal for ImmunoTherapy of Cancer. 6, 1, 76.

Research output: Contribution to journalArticle

Interleukin-2
Melanoma
Mutation
Antigen Presentation
Neoplasm Antigens
4 Citations (Scopus)

Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients with Advanced Unresectable Melanoma

Almutairi, A. R., Alkhatib, N. S., Oh, M., Curiel, C. N., Babiker, H. M., Cranmer, L. D., McBride, A. & Abraham, I. L., Jan 1 2018, (Accepted/In press) In : JAMA Dermatology.

Research output: Contribution to journalArticle

Disease-Free Survival
Cost-Benefit Analysis
Melanoma
Quality-Adjusted Life Years
Costs and Cost Analysis
19 Citations (Scopus)

Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients

Zager, J. S., Gastman, B. R., Leachman, S., Gonzalez, R. C., Fleming, M. D., Ferris, L. K., Ho, J., Miller, A. R., Cook, R. W., Covington, K. R., Meldi-Plasseraud, K., Middlebrook, B., Kaminester, L. H., Greisinger, A., Estrada, S. I., Pariser, D. M., Cranmer, L. D., Messina, J. L., Vetto, J. T., Wayne, J. D. & 3 others, Delman, K. A., Lawson, D. H. & Gerami, P., Feb 5 2018, In : BMC Cancer. 18, 1, 130.

Research output: Contribution to journalArticle

Transcriptome
Melanoma
Skin
Neoplasm Metastasis
Recurrence